Genmab - ADR

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022

AbbVie

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that AbbVie (NYSE: ABBV) will submit a conditional marketing authorization application (MAA) with the European Medicines Agency (EMA) for subcutaneous epcoritamab (DuoBody®-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), in the second half of 2022. Genmab recently announced that the company will submit a biologics licens

Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Genmab is receiving substantial and growing royalties from big pharma partners. The royalties are helping the company build its pipeline and to establish its own commercial infrastructure.

Genmab: A Royalty Powerhouse With A Strong Pipeline

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE™ NHL-1 phase 2 clinical trial evaluating subcutaneous epcoritamab (DuoBody®-CD3xCD20), an investigational bispecific antibody. In the study, treatment with epcoritamab demonstrated deep and durable responses with an overall response rate (ORR) of 63 percent and a complete response rate (CR) of 39 percent in patients who had previous

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab is one of my top picks in healthcare. The company expects to report impressive growth over the remainder of 2022 and beyond. Genmab has an imposing pipeline of proprietary and partnered programs that should provide additional growth opportunities.

Genmab: Looking For Growth At A Reasonable Price

Genmab Commences New Arbitration Under License Agreement With Janssen

Media Release COPENHAGEN, Denmark ; June 8 , 20 2 2 Genmab A/S (Nasdaq: GMAB ) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will participate in a fireside chat at the Goldman Sachs 4 3rd Annual Global Healthcare Conference in Rancho Palos Verdes, California 1 : 20 PM P D T on June 15 , 202 2 ( 4.20 PM EDT / 10.20 PM CEST). A webcast of the fireside chat will be available on Genmab's website at https://ir.genmab.com/events-and-presentations#content

Genmab to Participate in a Fireside Chat at the Goldman Sachs 43rd Annual Global Healthcare Conference

Seagen

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced interim data from the innovaTV 205 trial, which included data evaluating tisotumab vedotin (TIVDAK®) in combination with pembrolizumab (Cohort E) in patients with recurrent or metastatic cervical cancer (r/mCC) who have not received prior systemic therapy, with a confirmed objective response rate (ORR) of 41% (95% Confidence Interval [CI]: 24% to 59%) and median durabi

Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced interim data from the innovaTV 205 trial, which included data evaluating tisotumab vedotin (TIVDAK®) in combination with pembrolizumab (Cohort E) in patients with recurrent or metastatic cervical cancer (r/mCC) who have not received prior systemic therapy, with a confirmed objective response rate (ORR) of 41% (95% Confidence Interval [CI]: 24% to 59%) and median durabi

Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, will be presented at the European Hematology Association (EHA) Annual Congress, being held in Vienna, Austria, and virtually, June 9-12. The presentations will include data from various clinical trials, including multiple arms of the phase 1b/2 EPCORE™ NHL-2 trial, evaluating the safety and prelimi

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

Genmab A/S (GMAB) Q1 2022 Earning Conference Call May 11, 2022 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Conference Call Participants Peter Virgil - Citigroup James Gordon - JPMorgan Wimal Kapadia - Bernstein Peter Welford - Jefferies Michael Schmidt - Guggenheim Securities Asthika Goonewardene - Truist Securities Xian Deng - Berenberg Charlie Yang - Morgan Stanley Yaron Werber - Cowen & Co. Operator Hello, and welcome to the Genmab Q1 2022 Conference Call. Throughout the call, all participants will be in listen only mode.

Genmab A/S (GMAB) CEO Jan van de Winkel on Q1 2022 Results - Earning Call Transcript

May 11 , 202 2 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2022

Genmab Announces Financial Results for the First Quarter of 2022

Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Genmab (GMAB) Ahead of Earnings?

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022

Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate of 63%.

Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study

-          Based on topline results from the EPCORE™ NHL-1 clinical trial, AbbVie and Genmab will engage global regulatory authorities -          Data from the clinical trial to be presented at a future medical meeting -          Large B-cell lymphoma (LBCL) is a common form of non-Hodgkin's lymphoma (NHL) and currently has limited treatment options NORTH CHICAGO, Ill. and COPENHAGEN, Denmark , April 13, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2 clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody.

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Johnson & Johnson's (NYSE: JNJ) Janssen has won an arbitration against Genmab A/S (NASDAQ: GMAB) on two matters related to their licensing pact for multiple myeloma drug Darzalex (daratumumab). The first issue around daratumumab arose because Janssen announced a deal.

Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties

Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to the New Member of the Board of Directors and Grant of Restricted Stock Units and Warrants to Employees in Genmab

Toronto, Ontario--(Newsfile Corp. - March 14, 2022) - Xtra-Gold Resources Corp. (TSX: XTG) (OTCQB: XTGRF) ("Xtra- Gold" or the "Company") is pleased to announce today that the Toronto Stock Exchange ("TSX") has accepted a noticed filed by the Company of its intention to renew its prior normal course issuer bid for a further one year period. The Company intends to proceed with a normal course issuer bid to purchase up to 4,000,000 common shares of the Company (the "2022 Bid").

Genmab Announces the Nomination of a New Member of the Company's Board of Directors

Genmab enjoyed a strong 2021, recording revenues that have been able to maintain the majority of the growth seen in 2020.

Genmab: A Biotech Company On The Rise

Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for FL.

Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag

News for Genmab - ADR Stock (GMAB)